Small molecules which reverse Sorafenib treatment
Canned Analysis
FAIR Metrics
0 evaluations
General Information
AccessionDCA00012523
TitleSmall molecules which reverse Sorafenib treatment
DescriptionThe L1000 database was queried in order to identify small molecule perturbations which reverse the gene expression signature induced by Sorafenib treatment in the SLM2 melanoma cells cell type.
Analysis URLhttp://amp.pharm.mssm.edu/L1000CDS2/#/result/58d1d300e467bea600fb8dea
Upload DateSeptember 20, 2017
Uploadermaayanlab
Metadata
Analysis Curatormaroulisv
CREEDS IDdrug:3055
Cell TypeSLM2 melanoma cells
Drug NameSorafenib
DrugBank IDDB00398
Organismhuman
PubChem CID216239
SMILES IDCNC(=O)C1=NC=CC(=C1)OC2=CC=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F
L1000CDS2 parameters
Directionreverse
Characteristic Direction parameters
Control SamplesGSM957759, GSM957763
Perturbed SamplesGSM957760, GSM957764
Tools used in the analysis
Dataset Accession
L1000CDS2
Published August 2016
An ultra-fast LINCS L1000 Characteristic Direction signature search engine
7756
Characteristic Direction
Published March 2014
A geometrical multivariate approach to identify differentially expressed genes
26829
Datasets used in the analysis
Keyword
Tool Name
GSE39192
Gene Expression Omnibus
Synthetic lethal screening with small molecule inhibitors provides a pathway to rational combination therapies for melanoma
7
FAIR Evaluation
Sorry, you must be signed in to evaluate this object.